NASDAQ · FHTX
Healthcare · Biotechnology
$7.07
Up+$0.06 (+0.86%)
Updated Aug 23, 2026, 12:37 AM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
FHTX closed at $7.07 after 20 trading sessions, up 35.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $7.10 | $7.3484 | $6.95 | $7.07 | 536.55K |
| Aug 20, 2026 | $6.93 | $7.61 | $6.89 | $7.01 | 1.33M |
| Aug 19, 2026 | $6.94 | $7.17 | $6.77 | $7.06 | 335.84K |
| Aug 18, 2026 | $6.62 | $6.87 | $6.4272 | $6.75 | 153.92K |
| Aug 17, 2026 | $6.25 | $6.90 | $6.17 | $6.74 | 236.85K |
| Aug 14, 2026 | $6.47 | $6.6027 | $6.15 | $6.26 | 140.02K |
| Aug 13, 2026 | $6.64 | $6.80 | $6.47 | $6.49 | 214.42K |
| Aug 12, 2026 | $6.65 | $6.85 | $6.49 | $6.64 | 235.98K |
| Aug 11, 2026 | $6.21 | $6.825 | $6.21 | $6.59 | 383.57K |
| Aug 10, 2026 | $6.03 | $6.60 | $5.95 | $6.24 | 366.76K |
| Aug 7, 2026 | $5.64 | $6.17 | $5.515 | $6.07 | 280.9K |
| Aug 6, 2026 | $5.06 | $5.58 | $5.05 | $5.57 | 365.78K |
| Aug 5, 2026 | $4.86 | $4.95 | $4.73 | $4.88 | 158.84K |
| Aug 4, 2026 | $4.63 | $4.92 | $4.63 | $4.86 | 160.82K |
| Aug 3, 2026 | $4.55 | $4.72 | $4.47 | $4.61 | 214.17K |
| Jul 31, 2026 | $4.74 | $4.95 | $4.4054 | $4.53 | 157.61K |
| Jul 30, 2026 | $4.74 | $4.83 | $4.605 | $4.74 | 173.42K |
| Jul 29, 2026 | $5.14 | $5.25 | $4.71 | $4.74 | 201.57K |
| Jul 28, 2026 | $5.22 | $5.2247 | $5.01 | $5.13 | 159.62K |
| Jul 27, 2026 | $4.99 | $5.24 | $4.8701 | $5.20 | 159.32K |
The latest Smart Investors Daily articles mentioning FHTX.
FHTX research
Company profile and research snapshot.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 12, 2026 | Wedbush | Outperform | — |
| Mar 10, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 17, 2026 | Jefferies | Buy | — |
| Dec 18, 2025 | BTIG | Buy | — |
| Dec 4, 2025 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 6, 2026
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share
SeekingAlpha · Jun 9, 2026
Foghorn Therapeutics Inc. (FHTX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 1:30 PM EDTCompany ParticipantsAdrian H.
Yahoo · Feb 3, 2026
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have t
defenseworld.net · Dec 1, 2025
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FHTX.
